论文部分内容阅读
【目的】探讨羟苯磺酸钙联合奥美沙坦治疗糖尿病肾病（DN ）的蛋白尿临床效果。【方法】将2012年2月至2013年4月就诊于本院的DN伴蛋白尿患者70例，随机分为观察组（35例）和对照组（35例）。对照组采用奥美沙坦等降血糖、降血脂、降血压等常规治疗，观察组在对照组基础上添加羟苯磺酸钙治疗。对比两组治疗前及治疗12周后患者的24 h尿白蛋白排泄率（UAER）、单核细胞趋化蛋白-1（MCP-1）、尿α1-微球蛋白（α1-MG）水平。【结果】治疗12周后24hUAER观察组下降更为明显，差异具有统计学意义（ P ＜0．05）。观察组治疗总有效率为88％，显著高于对照组的68％，差异具有统计学意义（ P ＜0．05）。【结论】羟苯磺酸钙联合奥美沙坦治疗DN的蛋白尿有良好疗效，安全性好。“,”[Objective]To explore the clinical efficacy of calcium dobesilate combined with olmesartan for the treatment of proteinuria in diabetic nephropathy (DN) .[Methods]A total of 70 DN patients with proteinu-ria in our hospital from Feb .2012 to April 2013 were randomly divided into observation group ( n =35) and control group( n=35) .The control group received regular treatment including olmesartan and other hypogly-cemic hypotensive treatment .The observation group was additionally given calcium dobesilate based on the treatment of control group .The 24h-urinary albumin excretion rates(UAER) ,monocyte chemotactic protein-1 (MCP-1) and urinary α1-microglobulin(α1-MG) before and 12 weeks after treatment were compared between two groups .[Results] The 24h-UAER in observation group after 12 weeks of treatment was decreased more obviously ,and there was significant difference( P <0 .05) .The total effective rate of observation group was 88% ,which was markedly higher than that of control group(68% ) ,and there was significant difference( P<0 .05) .[Conclusion]Calcium dobesilate combined with olmesartan for the treatment of proteinuria in DN has good efficacy and safety .